Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03390790 · ClinicalTrials.gov registry record · Phase 4
Lidocaine for Pain After Urodynamic Testing
A Phase 4 study, sponsored by Atlantic Health System.
- Completed
- Registry status
- Phase 4
- Development phase
- 134
- Enrollment target
NCT03390790: Completed Phase 4 study, sponsored by Atlantic Health System.
NCT03390790 is a Phase 4 study that has completed, run by Atlantic Health System. The registered enrollment target is 134 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (74% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03390790, a Phase 4 study, has completed, sponsored by Atlantic Health System.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 134 participants
- Enrollment target
Study Summary
Urodynamic testing can be associated with mild discomfort, particularly at the time of insertion, repositioning, and removal of the bladder catheter (a tube inserted into the bladder via the urethra). Few studies have investigated ways to improve patient comfort during this procedure. In this study, the investigators want to see if applying external lidocaine (a numbing gel) prior to the procedure can help to minimize patient discomfort.
Primary Outcome
Participants will rate their pain according to a visual analog pain scale from 0 (no pain) to 100 (worst pain imaginable).
Interventions
- DRUG Lidocaine gel 2%
- OTHER Standard lubricant gel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 134 participants |
| Start Date | 2018-01-25 |
| Est. Completion | 2019-03-29 |
| Phase | Phase 4 |
What the finished NCT03390790 record still lists
NCT03390790 is an interventional study that assigns participants to a tested intervention. The registered 134 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (74% lower).
The record links to 0 conditions, and to 2 interventions - of which Lidocaine gel 2% is the first listed.
NCT03390790 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03390790 about?
NCT03390790 is a clinical study titled "Lidocaine for Pain After Urodynamic Testing". Urodynamic testing can be associated with mild discomfort, particularly at the time of insertion, repositioning, and removal of the bladder catheter (a tube inserted into the bladder via the urethra). Few studies have investigated ways to improve patient comfort during this procedure. In this study,...
What is the current status of trial NCT03390790?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 134 participants. The study started on 2018-01-25. Estimated completion is 2019-03-29.
What interventions are being tested in trial NCT03390790?
The interventions under investigation include: Lidocaine gel 2% (DRUG), Standard lubricant gel (OTHER).
Who is sponsoring clinical trial NCT03390790?
This trial is sponsored by Atlantic Health System, which has 43 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03390790's enrollment target sits among peer trials
134 606th of 2000 higher than 1,391 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02469662 · 134 participants · NA
Clinical Outcomes Study of the Nexel Total Elbow
- NCT03110822 · 134 participants · Phase 1
A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients
- NCT04678648 · 134 participants · Phase 1
A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
- NCT05264857 · 134 participants · NA
Decision Aid and Thyroid Nodules Management
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI